ADTX
Aditxt·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 3
Stock Price Surged Significantly
Significant Revenue Decline
Significant Net Income Decline
Low Cash Short-term Debt Ratio
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ADTX
Aditxt, Inc.
A biotech innovation company that develops technologies with a focus on monitoring and modulating the immune system
2569 Wyandotte Street, Suite 101, Mountain View, CA 94043
--
Aditxt, Inc., was incorporated under the laws of the State of Delaware on September 28, 2017. The company is a preclinical stage life sciences company dedicated to prolonging the lives of transplant patients and improving the quality of life of transplant patients. They have an exclusive global license for this nucleic acid-based technology called Apoptotic DNA Immunotherapy (ADi), which utilizes new methods to mimic their bodies' natural induction of tolerance to their own tissues. The company plans to develop ADi products for organ transplantation, skin grafting and wound healing, with an initial focus on skin grafts and other organ and tissue allografts.
Company Financials
EPS
ADTX has released its 2025 Q2 earnings. EPS was reported at -3.45, versus the expected 0, missing expectations. The chart below visualizes how ADTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ADTX has released its 2025 Q3 earnings report, with revenue of 748, reflecting a YoY change of -89.09%, and net profit of -24.21M, showing a YoY change of -246.80%. The Sankey diagram below clearly presents ADTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
